Antiaging Quantum Living Inc.

Antiaging Quantum Living Inc.

OOTC:AAQL
1.57
USD
-0.03
(-2.12%)
-0.03EPS
34.17MMarket Cap
Antiaging Quantum Living Inc.
OTC:AAQL
(OTC Markets)

Recent

price

1.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
USD
- -
- -
- -
- -
- -
- -
- -
0.03
0.03
0.05
Revenue per Share
- -
- -
- -
- -
- -
- -
-0.01
-0.02
-0.03
-0.03
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
-0.03
-0.03
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
-0.01
-0.04
-0.02
-0.03
Book Value per Share
- -
- -
- -
- -
- -
- -
-0.01
-0.04
-0.02
-0.03
Tangible Book Value per Share
30
30
30
30
30
30
30
30
31
33
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
1
Sales/Revenue/Turnover
96.12
- -
- -
-1,919.45
-608.24
-269.34
-5,507.63
-88.09
-80.43
-68.72
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
-1
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
53.97
- -
- -
-1,750.32
-586.97
-269.34
-5,507.01
-88.08
-80.98
-69.43
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-1
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
1
2
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-325.88
-147.86
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1
1
LT Borrowings
- -
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
21
21
34

Working Capital

USD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
1
1
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
1
2
3
Payables & Accruals
1
1
1
ST Debt
- -
1
1
Deferred Revenue
- -
- -
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
261.24%
-40.19%
Free Cash Flow
- -
417.53%
-65.4%
Net Income, GAAP
- -
213.55%
16.27%
Sales/Revenue/Turnover
- -
2,193.38%
26.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
2027
1
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.01
-0.01
- -
-0.01
-0.02
2026
- -
- -
-0.01
-0.01
-0.03
2027
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
Achison Inc. (NYSE: ACHN) operates as a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies targeting serious diseases, particularly in oncology and rare genetic disorders; its core pipeline includes targeted small molecule inhibitors such as oral drugs for hedgehog pathway inhibition and immuno-oncology agents; the company also provides contract research services and licensing agreements for proprietary compounds. Founded in 1994 and headquartered in Canton, Massachusetts, Achison serves pharmaceutical partners, healthcare providers, and patients primarily in North America and Europe, with expanding operations into Asia-Pacific markets through clinical trial collaborations. In late 2024, Achison announced a strategic merger with a leading immuno-oncology firm, enhancing its pipeline with two Phase III candidates; earlier in 2025, the company completed a $250 million funding round led by venture capital investors to support commercial launches; additionally, it rebranded select subsidiaries under a unified precision medicine division following regulatory approvals for its flagship hedgehog inhibitor in multiple indications.